Genoptix, which focuses on customized diagnostic services to hematologists and oncologists, filed terms Tuesday with the SEC. The company plans to offer 5 million shares, including 714 thousand shares from selling shareholders, at a price range of $14 to $16 per share. Lehman Brothers is the lead manager on the deal.
